Repay Holdings (RPAY) Issues 118,243 Inducement Shares to CFO
Rhea-AI Filing Summary
Repay Holdings Corp (RPAY) reported that Chief Financial Officer Robert Scott Houser was granted 118,243 restricted shares of Class A common stock on 09/08/2025. The award was made as an inducement outside the company’s Amended and Restated Omnibus Incentive Plan under NASDAQ Listing Rule 5635(c)(4). The restricted shares carry a $0 grant price and will vest in four equal annual installments beginning on 09/08/2026, meaning approximately 29,561 shares will vest each year if vesting conditions are met. After the grant, Mr. Houser beneficially owns 118,243 Class A shares directly.
Positive
- Inducement award aligns CFO incentives with shareholder outcomes through multi-year vesting
- Clear vesting schedule: four equal annual installments starting 09/08/2026 provides transparency on dilution timing
Negative
- None.
Insights
TL;DR: New CFO received a sizeable inducement grant of 118,243 restricted shares, vesting over four years, issued outside the omnibus plan.
This grant aligns senior executive pay with shareholder outcomes by using restricted stock that vests over multiple years, which can incentivize retention and longer-term performance. The award was granted as an inducement under NASDAQ rules, indicating it was a negotiated hire-related award rather than a routine plan grant. The $0 grant price shows these are typical restricted shares rather than a purchase-based award. Investors should note the vesting schedule (four equal annual installments starting 09/08/2026) when considering potential future share issuance and dilution timing.
TL;DR: Form 4 discloses a compliant inducement award; filing is routine and conforms to Section 16 reporting requirements.
The filing identifies the reporting person as the CFO and documents the non-derivative grant and resulting beneficial ownership of 118,243 Class A shares. The disclosure cites NASDAQ Listing Rule 5635(c)(4), which governs inducement awards outside an omnibus plan, suggesting the issuer followed the prescribed approval path. The form shows the transaction date (09/08/2025) and the filing signature via attorney-in-fact on 09/10/2025, consistent with timely reporting.